Update on the Calcium-Sensing Receptor

The cells of the human body have a receptor that is sensitive to extracellular calcium [calcium-sensing receptor (CaSR)] and whose tissue expression is decreased in patients with chronic kidney disease. The CaSR plays a key role both in the regulation of PTH secretion by parathyroid cells, as well as in calcium tubular reabsorption by renal tubular cells. Recent biochemical and cellular studies found that this receptor has peculiar functional characteristics. Furthermore, pharmacological research has brought to the marker agonists for CaSR (calcimimetics) that today are used for treating secondary hyperparathyroidism and may have an effect on cardiovascular and bone diseases in patients with chronic kidney disease. With regard to the latter, the EVOLVE and ADVANCE trials were dedicated to understanding the role of cinacalcet, a calcimimetic drug, in the prevention of vascular calcification and cardiovascular events in patients with chronic kidney disease. Research in this field has thus opened promising perspectives for the treatment of chronic kidney disease.

[1]  C. Dollery,et al.  Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women. , 2013, Bone.

[2]  D. Diz,et al.  Nitric-Oxide Synthase Knockout Modulates Ca2+-Sensing Receptor Expression and Signaling in Mouse Mesenteric Arteries , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[3]  R. Macleod,et al.  Extracellular calcium-sensing receptor/PTH knockout mice colons have increased Wnt/β-catenin signaling, reduced non-canonical Wnt signaling, and increased susceptibility to azoxymethane-induced aberrant crypt foci , 2013, Laboratory Investigation.

[4]  K. Nitta,et al.  Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism , 2013, Clinical and Experimental Nephrology.

[5]  K. Mahaffey,et al.  Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. , 2012, The New England journal of medicine.

[6]  E. Brown,et al.  Deficiency of the calcium-sensing receptor in the kidney causes parathyroid hormone-independent hypocalciuria. , 2012, Journal of the American Society of Nephrology : JASN.

[7]  P. Houillier,et al.  PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor. , 2012, The Journal of clinical investigation.

[8]  S. Zanos,et al.  Impact of Long-Term Cinacalcet, Ibandronate or Teriparatide Therapy on Bone Mineral Density of Hemodialysis Patients: A Pilot Study , 2012, American Journal of Nephrology.

[9]  G. Thiel,et al.  Transcriptional response to calcium-sensing receptor stimulation. , 2012, Endocrinology.

[10]  G. Breitwieser.  Minireview: the intimate link between calcium sensing receptor trafficking and signaling: implications for disorders of calcium homeostasis. , 2012, Molecular endocrinology.

[11]  J. Hou,et al.  Claudin‐14 regulates renal Ca++ transport in response to CaSR signalling via a novel microRNA pathway , 2012, The EMBO journal.

[12]  H. Genant,et al.  Ronacaleret, a calcium‐sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  D. Shoback,et al.  Osteoblast extracellular Ca2+‐sensing receptor regulates bone development, mineralization, and turnover , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  A. Cavanaugh,et al.  Agonist-Driven Maturation and Plasma Membrane Insertion of Calcium-Sensing Receptors Dynamically Control Signal Amplitude , 2011, Science Signaling.

[15]  M. Inaba,et al.  Effect of cinacalcet on bone mineral density of the radius in hemodialysis patients with secondary hyperparathyroidism. , 2011, Clinical nephrology.

[16]  J. Bilezikian,et al.  The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. , 2011, The Journal of clinical endocrinology and metabolism.

[17]  P. Raggi,et al.  The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  G. Sunder-Plassmann,et al.  Cinacalcet Decreases Bone Formation Rate in Hypercalcemic Hyperparathyroidism after Kidney Transplantation , 2010, American Journal of Nephrology.

[19]  E. Brown,et al.  Physiology and pathophysiology of the calcium-sensing receptor in the kidney. , 2010, American journal of physiology. Renal physiology.

[20]  G. Gambaro,et al.  Roles of calcium-sensing receptor (CaSR) in renal mineral ion transport. , 2009, Current pharmaceutical biotechnology.

[21]  E. Ritz,et al.  A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. , 2009, Kidney International.

[22]  Supplemental Tables,et al.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2009, Kidney international. Supplement.

[23]  N. Nagano,et al.  Cinacalcet suppresses calcification of the aorta and heart in uremic rats. , 2008, Kidney international.

[24]  T. Akizawa,et al.  Impact of Cinacalcet Hydrochloride on Bone Histology in Patients with Secondary Hyperparathyroidism , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[25]  D. Shoback,et al.  The Extracellular Calcium-Sensing Receptor (CaSR) Is a Critical Modulator of Skeletal Development , 2008, Science Signaling.

[26]  H. Malluche,et al.  An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. , 2008, Clinical nephrology.

[27]  H. Lehnert,et al.  Extracellular calcium-sensing receptor is functionally expressed in human artery. , 2007, American journal of physiology. Renal physiology.

[28]  R. Miller,et al.  The calcium-sensing receptor and its interacting proteins , 2007, Journal of cellular and molecular medicine.

[29]  F. J. Mendoza,et al.  Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. , 2006, Journal of the American Society of Nephrology : JASN.

[30]  G. Chertow,et al.  Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. , 2005, Kidney international.

[31]  G. Hendy,et al.  Human Calcium-sensing Receptor Gene , 2002, The Journal of Biological Chemistry.

[32]  R. Bukoski.  Dietary Ca2+ and blood pressure: evidence that Ca2+‐sensing receptor activated, sensory nerve dilator activity couples changes in interstitial Ca2+ with vascular tone , 2001 .

[33]  R. Bukoski.  Dietary Ca(2+) and blood pressure: evidence that Ca(2+)-sensing receptor activated, sensory nerve dilator activity couples changes in interstitial Ca(2+) with vascular tone. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  B. R. Smith,et al.  Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. , 2000, The Journal of clinical investigation.

[35]  M. Hediger,et al.  Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid , 1993, Nature.